Trump administration probe could upend widely used transgender youth treatment guidelines
The organization widely regarded as the leading authority on transgender medical treatment is facing allegations from the Federal Trade Commission that it built influential treatment guidelines for minors on evidence its own leaders privately acknowledged was limited and uncertain.
The complaint, filed in a Texas federal court by the Federal Trade Commission and the attorneys general of Alaska, Iowa, Nebraska and Texas, accuses World Professional Association for Transgender Health (WPATH) of developing and promoting guidance that healthcare providers relied upon when recommending puberty blockers, cross-sex hormones and sex-change procedures for minors.
The case could determine whether the medical guidance that shaped transgender treatment for thousands of children was built on solid evidence or agenda-driven speculation.
FTC Chairman Andrew Ferguson said the lawsuit is a consumer-protection case focused on whether families were properly informed about the risks and benefits of these treatments.
WASHINGTON POST ADMITS SCIENCE BEHIND PUBERTY BLOCKERS AND HORMONES FOR MINORS NOT CLEAR
"Children, but especially their parents, must have complete and truthful information when making decisions to purchase medical services," Ferguson said in a statement. "For decades, the FTC has taken action against entities that make deceptive and unsubstantiated health-related claims."
At the center of the lawsuit are allegations that WPATH publicly described its Standards of Care as evidence-based and rooted in expert consensus while some of the organization's own leaders privately acknowledged limitations in the available evidence.
The complaint cites a 2023 strategy memo from Standards of Care 8th edition lead author Dr. Eli Coleman stating that "all of us are painfully aware that there are many gaps in research to back up our recommendations."
ESSAY EXPOSES CRUMBLING MEDICAL CONSENSUS ON YOUTH GENDER SURGERY
It also references comments from Dr. Amy Tishelman, lead author of the organization's chapter on children, who acknowledged in an NPR interview that there was no established "research basis" for determining the best assessments or treatments for "transgender youth."
Federal regulators further allege WPATH removed age minimums from its 2022 Standards of Care for procedures including breast removal surgeries without scientific justification. According to the complaint, internal discussions revealed some WPATH leaders struggled to identify evidence-based reasons supporting the change.
Kurt Miceli, chief medical officer for Do No Harm, a medical ethics advocacy organization, said the allegations raise serious questions about how the organization's guidelines were developed.
PLASTIC SURGEON CITES 'EMOTIONAL BLACKMAIL,' POOR EVIDENCE IN WARNING AGAINST YOUTH GENDER SURGERIES
"The conflicts of interest that are within the standards of care are significant, and again, not brought to light, and this is part of that deception, and the concern that WPATH has sort of stated that the science is there behind pediatric medical transition when it is not."
Federal regulators allege that many of the clinicians and surgeons who helped draft WPATH's guidelines had financial and professional interests tied to the treatments being recommended.
"What WPATH did was stack the deck with folks who had a financial invested interest in promoting pediatric medical transition, and subsequently you get guidelines that push hormones, puberty blockers, and surgeries," Miceli said.
GENDER DYSPHORIA TREATMENTS POSE ‘SIGNIFICANT RISKS’ TO KIDS AND TEENS, HHS REPORT REVEALS
The lawsuit argues WPATH's influence extends far beyond its membership. Its Standards of Care have been widely cited throughout medicine and have helped shape treatment protocols, insurance coverage decisions and professional guidance across the United States.
WPATH is a co-sponsoring organization of the Endocrine Society's widely used clinical practice guideline on gender dysphoria and gender incongruence. The American Academy of Child and Adolescent Psychiatry describes WPATH and Endocrine Society guidance as the two most widely known clinical guidelines used by providers caring for youth with gender dysphoria.
Among the most serious allegations are claims that WPATH promoted pediatric transition procedures as "lifesaving" despite insufficient evidence that such interventions reduce suicide risk.
The complaint cites instances in which parents were allegedly asked whether they would "rather have a live daughter or a dead son" when considering treatment options for their children.
"When WPATH says that these are life-saving interventions, and then we hear physicians tell parents, 'Would you rather have a dead son or a living daughter?', and we hear that line repeated, which again is not supported by evidence by any means whatsoever," Miceli said.
"The benefits that WPATH is claiming are there actually aren't," Miceli told Fox News Digital. "In fact, the benefits are a very low certainty."
CHLOE COLE REVEALS INTENSE PRESSURE TO TRANSITION AS A MINOR, PARENTS WERE TOLD SHE'D 'PROBABLY DIE’
The complaint alleges that some minors who underwent medical transition experienced lasting complications, including chronic pain, sexual dysfunction, urinary incontinence, fertility concerns, nerve damage and ongoing psychological distress.
WPATH rejected the allegations Wednesday, calling the lawsuit politically motivated and legally flawed.
"This is the second time this year the Trump Administration has abused the authority of its agencies to interfere with Americans' rights to seek and obtain the healthcare that should be decided between a patient and their physician," the organization said in a statement.
PRISHA MOSLEY: DOCTORS TOOK MY BODY APART FOR GENDER ‘CARE.’ NOW THEY ADMIT IT WAS WRONG
"For more than 50 years, WPATH has been committed to developing guidelines informed by established scientific standards, expert consensus, and patient centered values."
Miceli said the lawsuit should prompt a broader review by medical organizations that have relied on WPATH's guidance.
"We need the American Medical Association, the Endocrine Society, the American Academy of Pediatrics, the American Psychiatric Association—the list goes on—we need them to look at the evidence as well, and they need to do that immediately," he said.
"The standards of care is terribly flawed, and again it has done considerable harm as a result," Miceli continued.